title: MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer.
authors.affiliation: Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Pedro Nazareth
authors.initials: PN
authors.lastname: Aguiar
authors.affiliation: Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Hakaru
authors.initials: H
authors.lastname: Tadokoro
authors.affiliation: Gastrointestinal Oncology Service, Gastroenterology Department, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Nora Manoukian
authors.initials: NM
authors.lastname: Forones
authors.affiliation: Department of Biomedical Sciences & Medicine, University of Algarve, Faro, Portugal.|Faculty of Medicine, University of Porto, Porto, Portugal.
authors.forename: Ramon Andrade
authors.initials: RA
authors.lastname: de Mello
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000150:complications / Q000276:immunology / Q000628:therapy*; D006801:Humans; D009154:Mutation / Q000235:genetics; D009362:Neoplasm Metastasis; D009386:Neoplastic Syndromes, Hereditary / Q000150:complications / Q000276:immunology / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*; D019139:Tumor Escape / Q000187:drug effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab
keywords: MMR; colorectal cancer; immunotherapy; pembrolizumab